B melanoma antigen 1
B melanoma antigen 1 (2-10) is a synthetic peptide fragment derived from the B melanoma antigen family, specifically corresponding to amino acid residues 2 through 10 of the parent protein. As a defined peptide epitope, it serves as a valuable tool in immunological and cancer research, particularly in the context of melanoma biology and antigen-specific investigations. Its well-characterized sequence enables precise studies of antigen recognition, T cell activation, and peptide-MHC interactions, making it a critical reagent for researchers exploring melanoma-associated immune responses and peptide-based assay development.
Epitope mapping: Researchers utilize this peptide fragment to define and characterize specific T cell epitopes within the B melanoma antigen family. By presenting the 2-10 amino acid sequence to immune cells, scientists can assess the specificity and strength of T cell recognition, facilitating the identification of immunodominant regions. This approach supports the refinement of antigenic targets for immunological assays and the development of tools for monitoring antigen-specific immune responses in experimental systems.
Peptide-MHC binding studies: The defined sequence of this peptide allows for detailed analysis of its binding affinity and stability with various major histocompatibility complex (MHC) molecules. Such studies are essential for understanding the molecular determinants of peptide presentation, T cell receptor engagement, and the structural basis of antigen recognition. Insights gained from these experiments contribute to the rational design of synthetic peptides for immune monitoring and vaccine research.
Immunoassay development: B melanoma antigen 1 (2-10) is frequently employed as a standard or control antigen in the development and validation of immunoassays, such as ELISPOT or intracellular cytokine staining protocols. Its use ensures assay specificity and sensitivity by providing a consistent target for immune cell stimulation and functional readouts. This supports the reliable quantification of antigen-specific responses in various research settings, including tumor immunology and basic immunological studies.
Peptide synthesis validation: As a short, well-defined peptide, the 2-10 fragment serves as an effective model for optimizing and validating solid-phase peptide synthesis protocols. Its sequence complexity and physicochemical properties allow peptide chemists to evaluate coupling efficiency, sequence fidelity, and purification strategies. This application is particularly relevant for quality control and methodological improvements in peptide production workflows.
Antigen processing research: The use of this peptide in studies of antigen processing and presentation enables researchers to dissect the mechanisms by which melanoma antigens are generated, processed, and displayed by antigen-presenting cells. By introducing the synthetic fragment into experimental systems, investigators can analyze proteolytic processing, transport, and MHC loading events, advancing the understanding of tumor antigen presentation pathways and their implications for immune surveillance.
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More